Estela Vega Alonso

A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida)

D. Amadori, M. Moroni, N. Ibrahim, 2021, Breast Cancer Research and Treatment.